Effects of SmacN7 inducing apoptosis of breast cancer cell MDA-MB-157 and its mechanism

doi:10.12047/j.cjap.5948.2020.134

Abstract

Abstract: Objective: To investigate the effects and molecular mechanisms of Second mitochondria-derived activator of caspase N7 (SmacN7) on the apoptosis of breast cancer cells MDA-MB-157. Methods: Breast cancer cells MDA-MB-157 were treated with SmacN7 at the concentrations of 0-20 μmol/L. The proliferation activity of the cells was detected by MTS method, apoptosis and cell cycle were analyzed by flow cytometry, karyotypic changes of MDA-MB-157 cells were observed by Hoechst33342 staining, mitochondrial membrane potential was detected by JC-1 staining, and LDH release experiment was used to detect the drug cytotoxicity. Real time PCR was used to analyze the transcription levels of genes in MDA-MB-157 cells. The effect of inhibiting breast cancer proliferation was confirmed by tumor inhibition experiments. Results: After treated with SmacN7, the inhibition rate of proliferation and apoptosis rate of breast cancer cells MDA-MB-157 were increased (P＜0.01), the karyotype changed significantly, the mitochondrial membrane potential in cells was decreased, and the LDH release was increased. The transcription levels of TRAIL, DR4, DR5, p53, PARP-1, Bax, Bid, BAK, caspase-3, caspase-8 and caspase-9 were up-regulated (P＜0.01), and the transcription levels of Ras, PI3K, AKT, mTOR, Bcl-2, Bcl-xL, MCL-1, Survivin, cIAP-1 and cIAP-2 were inhibited (P＜0.01). Conclusion: SmacN7 induces apoptosis of breast cancer cell MDA-MB-157 through TRAIL-mediated death receptor pathway and mitochondrial-mediated endogenous apoptosis pathway, and plays a role in anti-breast cancer.

Key words: SmacN7, breast cancer, TRAIL pathway, mitochondrial pathway, cell apoptosis

CLC Number:

R737.9

LYU Zi-yan, ZHANG Xiao-yan, CHEN Hong, JIANG Pan-ruo, CHEN Jia-yu. Effects of SmacN7 inducing apoptosis of breast cancer cell MDA-MB-157 and its mechanism[J]. CJAP, 2020, 36(6): 642-647.

References

[1] 郭艳婷, 王彦, 杜利清, 等. Tat-SmacN7对人乳腺癌细胞系的放射增敏作用[J]. 中华放射医学与防护杂志, 2014, 34(1): 13-17.
[2] 王彦, 杜利清, 徐畅, 等. Tat-SmacN7诱导肿瘤细胞辐射敏感性的机理研究 [J]. 辐射研究与辐射工艺学报, 2013, 31(6): 14-18.
[3] 杜亚南, 王彦, 刘强. Smac模拟物的抗肿瘤作用机制研究进展[J]. 国际生物医学工程杂志, 2017(1): 37-41.
[4] Zhang Y, Zhang G, Sun X, et al. Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation[J]. Oncology Letters, 2018, 15(5): 6233-6240.
[5] Song JL, Chen C, Yuan JP, et al. Family history of cancer other than breast or ovarian cancer in first-degree relatives is associated with poor breast cancer prognosis[J]. Breast, 2017, 32: 130-134.
[6] Beberok A, Wrze＇sniok D, Rok J, et al. Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway[J]. Int J Oncol, 2018, 52(5): 1727-1737.
[7] 王振威, 肖刚, 刘威, 等. 不同基因分型乳腺癌中Caspase-3、XIAP、Smac表达情况及与临床病理参数的关系[J]. 实用癌症杂志, 2019, 34(1): 22-25.
[8] 徐聂, 李昌林, 肖敏伟, 等. 乳腺癌组织中Livin和Smac的表达及其临床意义[J]. 肿瘤预防与治疗, 2019, 32(4): 324-330.
[9] Kretz AL, Trauzold A, Hillenbrand A, et al. TRAIL blazing strategies for cancer treatment.[J]. Cancers (Basel), 2019, 11: 456.
[10] Duan ZG, Wei B, Deng JJ, et al. The anti-tumor effect of ginsenoside Rh4 in MCF-7 breast cancer cells in vitro and in vivo[J]. Biochem Biophys Res Commun, 2018, 499: 482-487.
[11] Lin SC, Chu PY, Liao WT, et al. Glycyrrhizic acid induces human MDA-MB-231 breast cancer cell death and autophagy via the ROS-mitochondrial pathway[J]. Oncology Reports, 2018, 39 (2): 703-710.
[12] 张雷, 程龙球, 周兆, 等. 双氢青蒿素对Raji细胞放射敏感性的影响[J]. 中国应用生理学杂志, 2017, 33(5): 385-390.
[13] Tseng HS, Wang YF, Tzeng YM, et al. Aloe-emodin enhances tamoxifen cytotoxicity by suppressing Ras/ERK and PI3K/mTOR in breast cancer cells[J]. Am J Chin Med, 2017, 45(2): 337-350.
[14] Jelinek M, Kabelova A, Sramek J, et al. Differing mechanisms of death induction by fluorinated taxane SB-T-12854 in breast cancer cells.[J]. Anticancer Res, 2017, 37(4): 1581-1590.
[15] Xue M, Ji X, Xue C, et al. Caspase-dependent and caspase-independent induction of apoptosis in breast cancer by fucoidan via the PI3K/AKT/GSK3β pathway in vivo and in vitro[J]. Biomed Pharmacother, 2017, 94: 898-908.
[16] Ward GA,LewisEJ,Ahn JS et al. ASTX660, a novel non-peptidomimetic antagonist of cIAP1/2 and XIAP, potently induces TNFα-dependent apoptosis in cancer cell lines and inhibits tumor growth.[J]. Mol Cancer Ther, 2018, 17: 1381-1391.
[17] Shi Z, Hodges VM, Dunlop EA, et al. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line[J]. Mol Cancer Res, 2010, 8(4): 615-626.
[18] Serini S, Calviello G. Modulation of Ras/ERK and phosphoinositide signaling by long-Chain n-3 PUFA in breast cancer and their potential complementary role in combination with targeted drugs[J]. Nutrients, 2017, 9(3): 185.
[19] Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review[J]. Breast Cancer Res Treat, 2018, 169(6): 1-10.
[20] 奉水东, 伍迪, 杨丝丝, 等. 槟榔碱对人乳腺癌MCF-7细胞增殖和凋亡的影响[J]. 中国应用生理学杂志, 2016, 32(4): 370-372.
[21] Moulder D, Hatoum D, Tay E, et al. The roles of p53 in mitochondrial dynamics and cancer metabolism: The Pendulum between survival and death in breast cancer[J] ? Cancers, 2018, 10(6): 189.